Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
- Saturday, October 12, 2019, 7:17
- PR Newswire
- Add a comment
INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of…
About the Author
admin has written 21803 stories on this site.